Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

This research shows a full-dose booster of the vaccine was associated with stronger antibody responses than a half-dose boost; the magnitude of T-cell responses did not increase with either boost dose. These data support the two-dose regime being evaluated in phase 3 trials.

Nature Medicine